There was a decrease in the incidence of intraocular inflammation in the 28-week MAPLE study of abicipar pegol, Allergan and Molecular Partners announced in a press release.
The open-label study evaluated the safety of abicipar that was produced with a modified manufacturing process and used in 123 patients with neovascular age-related macular degeneration.
The incidence of intraocular inflammation was 8.9%, which was lower than the incidence observed in both the CEDAR and SEQUOIA phase 3 trials.
Allergan plans to file a biologics license application with the FDA for abicipar in (Read more...)
Uncategorized